Saturday, October 31, 2026

Salesforce Stock Drops 8% As Session Comes To An End On Wednesday, Underperforms Market

ViaNews Editorial Team

December 2, 2020

Salesforce Stock Drops 8% As Session Comes To An End On Wednesday, Underperforms Market
Even though Salesforce has been somewhat immune to the crisis, shares sliding 8.6% to $220.59 at 15:11 EST on Wednesday, after two sequential sessions in a row of losses. The New York Stock Exchange is falling 0.05% to $14,139.30, following yesterday's upward trend, on what up until now seems, a somewhat negative trend exchanging session today. Salesforce's last close was $241.35, 28.97% under its 52-week high of $284.50.

News about Salesforce today

Salesforce confirms deal to buy slack. According to today's article on The Wall Street Journal, "The $27.7 billion purchase, which still has to clear Slack shareholder and regulatory approval, would be Salesforce’s largest ever acquisition and boost its competition with rival Microsoft.." According to today's article on Bloomberg Quint, "Salesforce’s Benioff Escalates Microsoft Rivalry With Slack Deal." Salesforce falls 7% after confirming $27.7 billion slack acquisition and forecasting slower growth. According to today's article on Business Insider, "<figure> <img alt="Salesforce Marc Benioff" class="img-responsive imported-news-entry-img" src="https://images2.markets.businessinsider.com/5fc78fc050e71a00115585a7?format=jpeg" /> <figcaption>Salesforce CEO Marc Benioff <p class="copyright">Business Insider<!-- sh_cad_1 --> </figcaption> </figure><ul><li><a href="https://markets.." Stock alert: Salesforce tumbles 10%. According to today's article on Business Insider, "(RTTNews) - Shares of Salesforce.com, Inc."

Salesforce's Sales

Salesforce's sales growth is 13.8% for the ongoing quarter and 16.6% for the next. The company's growth estimates for the present quarter and the next is 30.3% and 12.9%, respectively.

Salesforce's Revenue

Year-on-year quarterly revenue growth grew by 20.1%, now sitting on 20.29B for the twelve trailing months.

Salesforce's Stock Top and Bottom Yearly Value

Salesforce's stock is valued at $220.59 at 15:11 EST, way under its 52-week high of $284.50 and way above its 52-week low of $115.29.

Salesforce's Moving Average

Salesforce's worth is way under its 50-day moving average of $251.35 and above its 200-day moving average of $220.48.

Previous days news about Salesforce

Salesforce to buy software maker slack for $27.7 billion. According to yesterday's article on Bloomberg Quint, "Salesforce agreed to buy Slack in one of the biggest technology deals of the year.." According to yesterday's article on MarketWatch, "Salesforce to buy Slack in deal worth $27.7 billion." Salesforce’s splashy slack deal isn't worth the risk. According to yesterday's article on Bloomberg Quint, "Salesforce’s Splashy Slack Deal Isn't Worth the Risk." Salesforce plus slack doesn't equal Microsoft. According to yesterday's article on The Wall Street Journal, "Its $27.7 billion deal for Slack steps up Salesforce’s competition with Microsoft, but it might take even more acquisitions to gain ground.."
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com